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Patients with diffuse large B cell lymphoma (DLBCL) who are not candidates for or recur after autologous stem cell
transplant have a poor overall prognosis. We conducted a phase II study of sorafenib (formerly BAY 43–9006) in the
treatment of relapsed DLBCL. Fourteen patients were enrolled and assessed for response. Median number of cycles
administered was 3 (range, 1–12). Common grade 3 toxicities included fatigue (29%), rash/desquamation (21%) and
diarrhea (14%). One complete response (CR) was observed (the 14th patient enrolled). Response rate was 7% (90%
CI, 0.4 – 30%). Duration of response was 6 months. Median progression-free survival (PFS) was 2 months (90% CI,
1 – 5 months). Median overall survival (OS) was 9 months (90% CI, 5 – 16 months). Although sorafenib has
demonstrated activity in solid malignancies it demonstrated low single agent activity in treatment of DLBCL.
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The non-Hodgkin lymphomas remain among the most
treatable forms of cancer. In spite of success with pre-
sent chemotherapy and antibody-based regimens, a large
subset of patients will recur after primary and secondary
treatment. While effective in many cases, chemotherapy
based treatment carries risks of substantial short and
long-term toxicity. Patients who relapse after standard
therapy may be eligible for high dose therapy with stem
cell transplant. This approach cures fewer than half of
patients with relapsed disease [1,2] and many patients
are not eligible on the basis of age or other comorbi-
dities. More effective, less toxic therapies are needed.
Ras oncogene activation plays an instrumental role
in carcinogenesis of several human tumor types
including several hematologic malignancies [3,4]. The
Ras/Raf/MEK/ERK kinase pathway may play a role in
pathogenesis, tumor signaling, apoptosis susceptibility,
and treatment resistance observed in several in vitro* Correspondence: dgreenwald@ccsb.org
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distribution, and reproduction in any mediumlymphoma models [5-10]. Vascular endothelial growth
factor also contributes to lymphoma formation and
progression and is an active area of therapeutic inves-
tigation [11-14] Sorafenib blocks tumor angiogenesis
by downstream inhibition of VEGFR-2/PDGFR-ß.
Sorafenib is a bis-aryl urea which inhibits the VEGFR-
2/PDGFR-ß and Ras/Raf/MEK/ERK signaling pathways
[15-17]. Sorafenib is approved by the United States Food
and Drug Administration for the treatment of renal cell
carcinoma and hepatocellular carcinoma [18,19]. Based
on the preclinical activity and toxicity profile we per-
formed a phase II clinical trial of sorafenib in patients
with relapsed DLBCL who failed or were not candidates
for autologous stem cell transplant.Materials and methods
We conducted a two-stage phase II study to assess safety
and activity of sorafenib in patients with relapsed aggressive
DLBCL. Response assessment was based upon the
criteria from the International Workshop to Standardize
Criteria for non-Hodgkin Lymphoma [20]. The study was
conducted through the Eastern Cooperative Group and
was approved by the respective Institutional Review Boards.
Patients with de novo or transformed DLBCL were eligibletral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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and had relapsed greater than 2 months after their last
treatment. Patients were required to have progressed after
or be ineligible for autologous stem cell transplant. Eligibil-
ity criteria included age greater than 18 years old, ECOG
performance status (PS) of 0–1, measurable disease by
computed tomography, absolute neutrophil count count
≥ 1,000/mm3, platelet count ≥ 75,000/mm3, normal serum
creatinine, total bilirubin ≤ 2.0 times institutional upper
limit of normal, AST ≤ 2.5 × institutional upper limit of
normal, ALT ≤ 2.5 times institutional upper limit of normal,
and normal PT/INR.
Patients received sorafenib at a dose of 400 mg PO BID
continuously in 28-day cycles. Patients who showed no
disease progression at the end of cycle 2 were to receive an
additional 4 cycles (for a total of 6 cycles) of sorafenib.
Patients who were responding or stable at the end of cycle
6 were to continue to receive 28-day cycles of sorafenib
until progressive disease or excessive toxicity.
Patients were instructed to take the tablets every 12 hours
with an 8 oz. glass of water, with or without food. If
sorafenib was taken with meals, patients were instructed to
take sorafenib with a moderate to low-fat meal. To track
compliance, patients were required to complete a pill calen-
dar. Adverse events reporting requirements and appropri-
ate dose modifications in case of toxicities were described
in the protocol. Patients were restaged for response after 2
and 6 cycles using the International Workshop Criteria.
Patients who progressed or had unacceptable toxicity at
any time discontinued therapy. Patients with stable disease
after 6 cycles continued treatment at physician’s discretion.
Responding patients were to continue on medication.
Statistical design and method
The study used a two-stage Simon design [21] to assess the
clinical efficacy of sorafenib in patients with relapsed
DLBCL. A total of 37 eligible patients were required to test
the null hypothesis that the true response rate for this
regimen is at most 5% versus the alternative hypothesis that
the true overall response rate is 20% or greater. In first
stage, 13 patients (12 eligible) were to be entered. If at least
1 response was observed among the 12 eligible patients, an
additional 28 patients (25 eligible) were to be entered.
Treatment would be considered promising with at least 4
responders out of the 37 eligible patients.
Descriptive statistics were used to characterize patients at
study entry. Toxicities were assessed using the NCI
Common Terminology Criteria for Adverse Events (CTCAE)
Version 3.0. Exact binomial confidence intervals were used
to describe response rate. Progression-free survival (PFS)
was defined as the time from study entry to progression or
death. Overall survival (OS) was defined as the time from
study entry until death from any cause. PFS and OS were
estimated using the Kaplan-Meier method.Results
Administrative information
The study was activated on October 25, 2005, and was
suspended on December 15, 2006 for pre-planned response
evaluations after accruing 14 patients. No response was
observed in the first 12 eligible patients. Patient #14 was
enrolled prior to notice of accrual suspension for planned
response assessment. Although 1 complete response (CR)
was later confirmed, this patient (the 14th patient enrolled)
was not among the first 12 eligible patients. Based on the
initial trial design of lack of response activity for the first 13
patients, the study was terminated on September 25, 2007.
The median follow-up was 36 months. Eight ECOG institu-
tions contributed patients to the study. All 14 patients were
eligible. Central pathology review was done for 11 (79%)
and 3 cases were unavailable for central review.
Patient characteristics
Patient characteristics at study entry are summarized in
Table 1. Patients ranged in age from 38 to 88 years, with a
median of 69.5 years. All patients were white, and 64% were
males. Seven (50%) patients had ECOG PS of 0, and the
other 7 (50%) had PS of 1. Eight (57%) had no extra-
lymphatic sites involved, 1 (7%) had one site, 3 (21%) had
two sites, and 2 (14%) had more than two sites. One patient
(7%) had bone marrow involvement, 6 (43%) had elevated
LDH, and 5 (36%) had lymph node or aggregate with a
diameter > 5 cm. None of the patients had B symptoms
present or mediastinal mass. All patients had prior chemo-
therapy, 4 (29%) had prior radiation therapy, 1 (7%) had
prior surgery with therapeutic intent, 3 (21%) had prior
bone marrow transplant (autologous), and 1 (7%) had
radioimmunotherapy (Zevalin).
Treatment
All 14 patients started protocol treatment. Table 2 shows
the number of cycles administered and reasons for discon-
tinuing treatments. The median number of cycles adminis-
tered was 3 (range, 1–12). Seven patients (50%) went off
treatment due to disease progression, with only one receiv-
ing more than six cycles of therapy. Three (21%) went off
treatment due to adverse events during cycle 1. Two
patients withdrew after cycle 2 and cycle 3, one started
alternative therapy (external beam radiation) after cycle 3,
and one was taken off the study after cycle 6 by treating
physician.
Toxicity
Table 3 summarizes toxicities classified at least possibly
treatment related. There were no treatment-related deaths.
Grade 4 toxicities included one thrombocytopenia (7%) and
one fatigue (7%). Common grade 3 toxicities were fatigue
(4 cases, 29%), rash/desquamation (3 cases, 21%) and
diarrhea (2 cases, 14%).
Table 2 Cycles received and off treatment reasons
Cycles
Reasons off treatment 1 2 3 5 6 12 Total
(n) (n) (n) (n) (n) (n) (n) (%)
Disease progression 1 1 1 1 2 1 7 50
Adverse events 3 3 21
Patient withdrawal 1 1 2 14
Alternative therapy 1 1 7
Other* 1 1 7
Total 4 2 3 1 3 1 14 100
* 14009: MD decision to withdraw due to lack of efficacy and side effects.
Table 3 Treatment related toxicities
Arm A (N = 14)
Grade
1,2 3 4 5
(n) (n) (n) (n)
Allergic reaction 1 - - -
Hemoglobin 5 - - -
Leukocytes - 1 - -
Neutrophils 1 1 - -
Platelets 3 1 1 -
Hypertension 6 1 - -
Fatigue 7 4 1 -
Weight loss 1 - - -
Flushing 1 - - -
Alopecia 1 - - -
Pruritus/itching 1 - - -
Rash/desquamation 5 3 - -
Hand-foot reaction 3 1 - -
Skin-other 1 - - -
Anorexia 3 - - -
Constipation 2 - - -
Dehydration - 1 - -
Diarrhea w/o prior colostomy 6 2 - -
Flatulence 1 - - -
Dyspepsia 3 - - -
Muco/stomatitis (symptom) oral cavity 2 - - -
Nausea 1 1 - -
GI-other 1 - - -
Infection Gr0-2 neut, urinary tract 1 - - -
Infection w/ unk ANC upper airway NOS 1 - - -
ALT, SGPT 4 - - -
AST, SGOT 5 - - -
Bilirubin 3 - - -
Hyponatremia - 1 - -
Nonneuropathic generalized weakness - 1 - -
Musculoskeletal/soft tissue-other 1 - - -
Dizziness 1 1 - -
Neuropathy-sensory 2 - - -
Extremity-limb, pain 1 - - -
Head/headache 1 - - -
Joint, pain 1 1 - -
Muscle, pain 2 - - -
Dyspnea 1 - - -
Worst degree 5 7 2 -
Table 1 Baseline characteristics
N %
Total number of patients 14
Age














Elevated LDH 6 43
Bone Marrow Involvement 1 7
B symptom 0 0
Mediastinal mass 0 0
Lymph node or aggregate with a diameter >5 cm 5 36
Prior Treatment
Prior Chemotherapy 14 100
Prior Immunotherapy 4 29
Prior Radiation Therapy 4 29
Prior Surgery (with therapeutic intent) 1 7
Prior Bone Marrow Transplant* 3 21
Other Prior Therapy** 1 7
* All three are autologous BMT.
** Patient 14002: ZEVALIN® (ibritumomab tiuxetan).
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Figure 1 Progression-free survival (PFS).
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Table 4 shows the best overall response. One patient
(14014) had complete response (CR) at post cycle 6 disease
assessment. This was the only response. Response rate was
7% (90% CI, 0.4 – 30%) with a duration 6 months. The
patient received a total of 12 cycles of protocol therapy
before disease progression. Central pathology review
confirmed unclassifiable B-cell lymphoma for this patient.
Five patients (36%) had stable disease and 7 (50%) had
progression as their best overall response. One patient
(14012) was not evaluable for response because he was
taken off study due to toxicities after receiving only 1 cycle
of protocol therapy and never had follow-up disease
evaluations.
Progression-free survival
Figure 1 shows PFS. Thirteen patients (93%) had docu-
mented progression. One patient never had follow-up
disease evaluations, and therefore PFS was censored at time
zero. Median PFS was 2 months (90% CI, 1 – 5 months).
Overall survival
Figure 2 shows OS. Thirteen patients (93%) have died.
Median survival was 9 months (90% CI, 5 – 16 months).
Discussion
Sorafenib was reasonably well tolerated in pretreated pa-
tients with relapsed DLBCL. The toxicity profile was simi-
lar to that described in other disease trials with this agent
[22]. One episode of grade 4 thrombocytopenia and one
episode of grade 4 fatigue were observed. We demon-
strated one complete response in a patient who subse-
quently progressed. Based on the analysis of the initial
stage we did not meet our predefined primary end point
of a 20% confirmed response rate as indicative for add-
itional study of the drug. Although cytostatic effects of
targeted agents have demonstrated improvements in PFS
and OS through disease stability in other malignancies,
the majority of the patients in this study succumbed to
progressive disease. Other groups have evaluated the
clinical activity of sorafenib and sunitinib in treatment
of relapsed diffuse large B-cell lymphoma with re-
ported overall response rates of 13 and 0% respectively
[23,24]. When compared with previous results of agentsTable 4 Best overall response
Response N %
Complete Response (CR) 1 7
Stable Disease (SD) 5 36
Progressive Disease (PD) 7 50
Unevaluable * 1 7
* Patient 14012 was unevaluable because he was taken off study after
receiving only one cycle of protocol therapy due to adverse events, and never
had follow-up disease evaluations.undergoing evaluation for treatment of relapsed DLBCL,
the results in this phase II trial showed less activity com-
pared with agents considered to have clinically meaningful
therapeutic effect including lenolidomide [25]. Therapies
which target the B cell receptor pathway appear toFigure 2 Overall survival (OS).
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investigation [26]. This was a small exploratory study
intended to assess safety and activity of sorefenib in this
population. It has not been tested in combination with
standard therapy and it is unknown whether it might
potentiate or enhance toxicity of standard therapy.
Such combinations could be considered for exploration
if additional preclinical data were supportive. On the
basis of poor therapeutic efficacy observed in this trial
additional targeted therapies should be explored.
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